Matches in Wikidata for { <http://www.wikidata.org/entity/Q79111630> ?p ?o ?g. }
Showing items 1 to 37 of
37
with 100 items per page.
- Q79111630 description "clinical trial" @default.
- Q79111630 description "ensayu clínicu" @default.
- Q79111630 description "klinisch onderzoek" @default.
- Q79111630 description "клінічне випробування" @default.
- Q79111630 name "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 name "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 type Item @default.
- Q79111630 label "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 label "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 prefLabel "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 prefLabel "A Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 P1050 Q79111630-1250DD7D-A0B5-4975-9EB7-B5763861898F @default.
- Q79111630 P1132 Q79111630-9C59A42F-1B54-4A7A-ABC8-C3389D3B7590 @default.
- Q79111630 P1476 Q79111630-DF18FE87-2220-4573-8467-DABDFA0F07F6 @default.
- Q79111630 P1813 Q79111630-4B39A22F-4B04-4B0F-9250-84369771F98C @default.
- Q79111630 P2899 Q79111630-6EC283E0-74B0-4572-9FD1-634DA3A13A03 @default.
- Q79111630 P3098 Q79111630-0C017EDC-4E7C-4B85-8C7A-1F1F3E104E0C @default.
- Q79111630 P31 Q79111630-4A61028B-C2E0-4769-A94E-0B512B3138C7 @default.
- Q79111630 P4135 Q79111630-140F17DC-BC65-45C6-9074-FBF5821B5C62 @default.
- Q79111630 P4844 Q79111630-72F6CEA1-2CE3-4D25-8674-639E8FDD9FB4 @default.
- Q79111630 P580 Q79111630-0FC78F01-8CF4-47FB-A2B3-058449375EF3 @default.
- Q79111630 P582 Q79111630-949FF2EF-53E7-453D-846F-0590B54D5BAB @default.
- Q79111630 P6099 Q79111630-964E7D72-90B2-4C7C-AA56-F81543FF0F0E @default.
- Q79111630 P8363 Q79111630-95F4315B-E188-4C5F-A18E-E1EA8ADC0914 @default.
- Q79111630 P1050 Q179630 @default.
- Q79111630 P1132 "+120" @default.
- Q79111630 P1476 "A Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled, 24-week Phase 3 Study With an Open-label Extension to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)" @default.
- Q79111630 P1813 "NATRON" @default.
- Q79111630 P2899 "+12" @default.
- Q79111630 P3098 "NCT04191304" @default.
- Q79111630 P31 Q30612 @default.
- Q79111630 P4135 "+130" @default.
- Q79111630 P4844 Q3638304 @default.
- Q79111630 P580 "2020-01-06T00:00:00Z" @default.
- Q79111630 P582 "2022-06-26T00:00:00Z" @default.
- Q79111630 P6099 Q42824827 @default.
- Q79111630 P8363 Q78089383 @default.